Clinical Trial Results:
Non-inferiority, Randomized, Observer-blind, two Parallel Group, Clinical Trial for Comparing the Efficacy and Tolerability of a new Generic BAC-free Formulation of Latanoprost 0.05 mg/mL eye drops, solution in single-dose container vs Xalatan® eye drops in Patients with Open Angle Glaucoma or Ocular Hypertension
Summary
|
|
EudraCT number |
2020-004307-14 |
Trial protocol |
GR |
Global end of trial date |
30 Dec 2021
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
24 Aug 2023
|
First version publication date |
24 Aug 2023
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
BECRO/ACT/LATANOS
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
actrevo GmbH
|
||
Sponsor organisation address |
Großer Burstah 25, Hamburg, Germany, 20457
|
||
Public contact |
actrevo GmbH, actrevo GmbH, +49 4022864810, info@actrevo.com
|
||
Scientific contact |
actrevo GmbH, actrevo GmbH, +49 4022864810, info@actrevo.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
25 Feb 2022
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
30 Dec 2021
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
30 Dec 2021
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To confirm the clinical non-inferiority of a generic BAC-free formulation of Latanoprost 0.05 mg/mL eye drops, solution in single-dose container with the marketed preservative-containing Xalatan® eye drops in patients with open angle glaucoma or ocular hypertension (IOP ≥22 mmHg) by examining the change of IOP at 08:00 am from end of study to baseline.
|
||
Protection of trial subjects |
The study was in compliance with the ethical principles derived from the declaration of Helsinki, the International Conference on Harmonisation (ICH) and the further guidelines in place on Good Clinical Practice (GCP). All the local regulatory requirements pertinent to the safety of trial subjects were followed during the conduct of the trial.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
25 Jun 2021
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Greece: 170
|
||
Worldwide total number of subjects |
170
|
||
EEA total number of subjects |
170
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
60
|
||
From 65 to 84 years |
103
|
||
85 years and over |
7
|
|
||||||||||||||||||||||
Recruitment
|
||||||||||||||||||||||
Recruitment details |
This was an observer-blind, two parallel group, randomized, multi-centre clinical phase III trial planned to enrol 170 patients. Patients diagnosed with open-angle glaucoma or ocular hypertension and IOP ≥22 mmHg were selected to participate in the study. | |||||||||||||||||||||
Pre-assignment
|
||||||||||||||||||||||
Screening details |
A total of 170 patients who met the inclusion and exclusion criteria signed the ICF and were initially selected to participate in the study. No screening period with induction therapy was foreseen. | |||||||||||||||||||||
Period 1
|
||||||||||||||||||||||
Period 1 title |
Overall trial (overall period)
|
|||||||||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||
Blinding used |
Single blind | |||||||||||||||||||||
Roles blinded |
Assessor [1] | |||||||||||||||||||||
Blinding implementation details |
The study was performed as observer-blind because of the differences in the packaging of IMPs. The test product was a preservative-free preparation in single-dose container whereas the reference product was supplied as multi-dose bottle. In the clinical trial site, there were "blind" and "non-blind" clinical trial staff. The "blind" staff contacted the patients and perform all trial-related examinations while the "non-blind" staff was responsible for distributing the drugs (IMPs).
|
|||||||||||||||||||||
Arms
|
||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||
Arm title
|
Latanoprost | |||||||||||||||||||||
Arm description |
A new preservative-free formulation of Latanoprost 0.05 mg/mL eye drops, solution in single-dose container in the treatment of open-angle glaucoma or ocular hypertension. | |||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||
Investigational medicinal product name |
Preservative-free Latanoprost 0.05 mg/mL eye drops, solution
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
BAC-free Latanoprost 0.05 mg/mL eye drops, solution
|
|||||||||||||||||||||
Pharmaceutical forms |
Eye drops, solution in single-dose container
|
|||||||||||||||||||||
Routes of administration |
Ophthalmic use
|
|||||||||||||||||||||
Dosage and administration details |
Product was self-administered by the patient as indicated: One drop in the affected eye(s) once daily in the evening.
|
|||||||||||||||||||||
Arm title
|
Xalatan® | |||||||||||||||||||||
Arm description |
The preserved medicinal product Xalatan® in the treatment of open-angle glaucoma or ocular hypertension. The reference product is marketed in a multi-dose bottle. | |||||||||||||||||||||
Arm type |
Active comparator | |||||||||||||||||||||
Investigational medicinal product name |
Xalatan® eye drops, solution
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
BAC-preserved Latanoprost 0.05 mg/mL eye drops, solution
|
|||||||||||||||||||||
Pharmaceutical forms |
Eye drops, solution
|
|||||||||||||||||||||
Routes of administration |
Ophthalmic use
|
|||||||||||||||||||||
Dosage and administration details |
Product was self-administered by the patient as indicated: One drop in the affected eye(s) once daily in the evening.
|
|||||||||||||||||||||
Notes [1] - The roles blinded appear inconsistent with a simple blinded trial. Justification: The study design was "observer-blind". |
||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Latanoprost
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
A new preservative-free formulation of Latanoprost 0.05 mg/mL eye drops, solution in single-dose container in the treatment of open-angle glaucoma or ocular hypertension. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Xalatan®
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
The preserved medicinal product Xalatan® in the treatment of open-angle glaucoma or ocular hypertension. The reference product is marketed in a multi-dose bottle. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Intent-to-treat (ITT) population
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Intention-to-treat | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
The intent-to-treat (ITT) analysis includes all randomized patients who had at least one post-baseline IOP measurement.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Per protocol (PP) population
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Per protocol | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
The per protocol (PP) analysis includes all those of the ITT population who had no major protocol violations, who completed IOP measurements, who completed at least 12 weeks of treatment with the last dose administered before the 12-week visit, and who did not take prohibited concurrent medication.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Safety population (SP)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Safety analysis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
The safety population (SP) comprises all patients who have received at least 1 eye drop of the test or the reference medication.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Latanoprost
|
||
Reporting group description |
A new preservative-free formulation of Latanoprost 0.05 mg/mL eye drops, solution in single-dose container in the treatment of open-angle glaucoma or ocular hypertension. | ||
Reporting group title |
Xalatan®
|
||
Reporting group description |
The preserved medicinal product Xalatan® in the treatment of open-angle glaucoma or ocular hypertension. The reference product is marketed in a multi-dose bottle. | ||
Subject analysis set title |
Intent-to-treat (ITT) population
|
||
Subject analysis set type |
Intention-to-treat | ||
Subject analysis set description |
The intent-to-treat (ITT) analysis includes all randomized patients who had at least one post-baseline IOP measurement.
|
||
Subject analysis set title |
Per protocol (PP) population
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
The per protocol (PP) analysis includes all those of the ITT population who had no major protocol violations, who completed IOP measurements, who completed at least 12 weeks of treatment with the last dose administered before the 12-week visit, and who did not take prohibited concurrent medication.
|
||
Subject analysis set title |
Safety population (SP)
|
||
Subject analysis set type |
Safety analysis | ||
Subject analysis set description |
The safety population (SP) comprises all patients who have received at least 1 eye drop of the test or the reference medication.
|
|
|||||||||||||||||||||||||
End point title |
Change in IOP in study eye from baseline to last visit | ||||||||||||||||||||||||
End point description |
The primary endpoint for evaluating the efficacy was the change in IOP at 08:00 am in study eye from end of treatment (week 12) to baseline (week 0) in subjects treated with the test product as compared to subjects treated with the reference product. According to the clinical protocol, the non-inferiority of the test product was evaluated based on the intent-to-treat (ITT) population.
|
||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||
End point timeframe |
Between baseline (week 0) to last visit (week 12)
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
Statistical analysis title |
Change in IOP in study eye | ||||||||||||||||||||||||
Statistical analysis description |
The primary endpoint is the change in IOP at 08:00 am in study eye from end of treatment (week 12) to baseline (week 0) in subjects treated with the test product as compared to subjects treated with the reference product. The analysis of covariance (ANCOVA) model was used to analyse the change in IOP with baseline IOP as the covariate, and treatment as a factor. The treatment difference and a two-sided 95 % confidence interval (CI) for the difference have been calculated.
|
||||||||||||||||||||||||
Comparison groups |
Latanoprost v Xalatan®
|
||||||||||||||||||||||||
Number of subjects included in analysis |
169
|
||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||
Analysis type |
non-inferiority [1] | ||||||||||||||||||||||||
P-value |
< 0.05 [2] | ||||||||||||||||||||||||
Method |
ANCOVA | ||||||||||||||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||
lower limit |
-0.547 | ||||||||||||||||||||||||
upper limit |
0.994 | ||||||||||||||||||||||||
Variability estimate |
Standard deviation
|
||||||||||||||||||||||||
Notes [1] - The generic preservative-free test product Latanoprost 0.05 mg/mL eye drops, solution in single-dose container is considered to be non-inferior to the marketed reference Xalatan® (preserved with BAC) if the upper limit of the 95 % CI of the difference is <1.5 mmHg. The primary analysis is based on the ITT analysis; the per protocol (PP) analysis is used to validate the results of the ITT analysis. [2] - A statistical result is considered significant at P <0.05. |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
All adverse events occurring during the clinical study were documented.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
25.0
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Latanoprost
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Test product | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Xalatan®
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Reference product | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |